A life sciences industrial strategy out this week provided long-term guidance for supporting and enhancing growth in the sector in the UK.
Illumina's BaseSpace Variant Interpreter encompasses standards for analysis and interpretation developed under a partnership between the firm and Genomics England.
Core elements of the new program include integrating genomic data into electronic medical records and the establishment of a national genome center.
Sequencing is enabling the roots of some rare diseases to be determined, the Financial Times reports.
Congenica will use the proceeds to establish its presence in the US and China, where it will court not only clinical genetics labs, but specialists, academics, biotech, and pharma.
The company will use the proceeds from the round to invest in sales and marketing efforts for its Sapientia clinical genome analysis platform, as well as for R&D.
Genomics England will use the product to aid scientists and clinicians in 13 National Health Service Genomic Medical Centres with clinical reporting and interpretation.
The center, which is seen as a bellwether for integrating genomic information with EMRs, will use the data to inform efforts to prevent chronic, common diseases.
Genomics plc will analyze de-identified genomics data for the consortium to inform pharmaceutical research and development investment decisions.
Genomics England will use the system to help in its clinical reporting for the 100,000 Genome Project's cancer program.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.